These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

177 related items for PubMed ID: 16899504

  • 1. Mycophenolate mofetil in diffuse cutaneous systemic sclerosis--a retrospective analysis.
    Nihtyanova SI, Brough GM, Black CM, Denton CP.
    Rheumatology (Oxford); 2007 Mar; 46(3):442-5. PubMed ID: 16899504
    [Abstract] [Full Text] [Related]

  • 2. Long-term efficacy and tolerability of mycophenolate mofetil therapy in diffuse scleroderma skin disease.
    Boulos D, Ngian GS, Rajadurai A, Elford K, Stevens W, Proudman S, Owen C, Roddy J, Nikpour M, Youssef P, Hill C, Sahhar J.
    Int J Rheum Dis; 2017 Apr; 20(4):481-488. PubMed ID: 28337853
    [Abstract] [Full Text] [Related]

  • 3. A prospective observational study of mycophenolate mofetil treatment in progressive diffuse cutaneous systemic sclerosis of recent onset.
    Mendoza FA, Nagle SJ, Lee JB, Jimenez SA.
    J Rheumatol; 2012 Jun; 39(6):1241-7. PubMed ID: 22467932
    [Abstract] [Full Text] [Related]

  • 4. Recurrence of progressive skin involvement following discontinuation or dose reduction of Mycophenolate Mofetil treatment in patients with diffuse Systemic Sclerosis.
    Mendoza FA, Lee-Ching C, Jimenez SA.
    Semin Arthritis Rheum; 2020 Feb; 50(1):135-139. PubMed ID: 31311679
    [Abstract] [Full Text] [Related]

  • 5. Mycophenolate mofetil is an effective and safe option for the management of systemic sclerosis-associated interstitial lung disease: results from the Australian Scleroderma Cohort Study.
    Owen C, Ngian GS, Elford K, Moore O, Stevens W, Nikpour M, Rabusa C, Proudman S, Roddy J, Zochling J, Hill C, Sturgess A, Tymms K, Youssef P, Sahhar J.
    Clin Exp Rheumatol; 2016 Feb; 34 Suppl 100(5):170-176. PubMed ID: 27049330
    [Abstract] [Full Text] [Related]

  • 6. Long-term experience of mycophenolate mofetil for treatment of diffuse cutaneous systemic sclerosis.
    Le EN, Wigley FM, Shah AA, Boin F, Hummers LK.
    Ann Rheum Dis; 2011 Jun; 70(6):1104-7. PubMed ID: 21378404
    [Abstract] [Full Text] [Related]

  • 7. Efficacy of Mycophenolate Mofetil and Oral Cyclophosphamide on Skin Thickness: Post Hoc Analyses From Two Randomized Placebo-Controlled Trials.
    Namas R, Tashkin DP, Furst DE, Wilhalme H, Tseng CH, Roth MD, Kafaja S, Volkmann E, Clements PJ, Khanna D, Participants in the Scleroderma Lung Study I and members of the Scleroderma Lung Study II Research Group.
    Arthritis Care Res (Hoboken); 2018 Mar; 70(3):439-444. PubMed ID: 28544580
    [Abstract] [Full Text] [Related]

  • 8. Effectiveness and safety of mycophenolate mofetil in idiopathic pulmonary fibrosis.
    Nambiar AM, Anzueto AR, Peters JI.
    PLoS One; 2017 Mar; 12(4):e0176312. PubMed ID: 28441449
    [Abstract] [Full Text] [Related]

  • 9. Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease.
    Liossis SN, Bounas A, Andonopoulos AP.
    Rheumatology (Oxford); 2006 Aug; 45(8):1005-8. PubMed ID: 16490756
    [Abstract] [Full Text] [Related]

  • 10. Mycophenolate mofetil for the treatment of scleritis.
    Sen HN, Suhler EB, Al-Khatib SQ, Djalilian AR, Nussenblatt RB, Buggage RR.
    Ophthalmology; 2003 Sep; 110(9):1750-5. PubMed ID: 13129873
    [Abstract] [Full Text] [Related]

  • 11. A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis.
    Derk CT, Grace E, Shenin M, Naik M, Schulz S, Xiong W.
    Rheumatology (Oxford); 2009 Dec; 48(12):1595-9. PubMed ID: 19846575
    [Abstract] [Full Text] [Related]

  • 12. Long-term outcome of gastrointestinal complications in renal transplant patients treated with mycophenolate mofetil.
    Hardinger KL, Brennan DC, Lowell J, Schnitzler MA.
    Transpl Int; 2004 Nov; 17(10):609-16. PubMed ID: 15517170
    [Abstract] [Full Text] [Related]

  • 13. Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS).
    Herrick AL, Pan X, Peytrignet S, Lunt M, Hesselstrand R, Mouthon L, Silman A, Brown E, Czirják L, Distler JHW, Distler O, Fligelstone K, Gregory WJ, Ochiel R, Vonk M, Ancuţa C, Ong VH, Farge D, Hudson M, Matucci-Cerinic M, Balbir-Gurman A, Midtvedt Ø, Jordan AC, Jobanputra P, Stevens W, Moinzadeh P, Hall FC, Agard C, Anderson ME, Diot E, Madhok R, Akil M, Buch MH, Chung L, Damjanov N, Gunawardena H, Lanyon P, Ahmad Y, Chakravarty K, Jacobsen S, MacGregor AJ, McHugh N, Müller-Ladner U, Riemekasten G, Becker M, Roddy J, Carreira PE, Fauchais AL, Hachulla E, Hamilton J, İnanç M, McLaren JS, van Laar JM, Pathare S, Proudman S, Rudin A, Sahhar J, Coppere B, Serratrice C, Sheeran T, Veale DJ, Grange C, Trad GS, Denton CP.
    Ann Rheum Dis; 2017 Jul; 76(7):1207-1218. PubMed ID: 28188239
    [Abstract] [Full Text] [Related]

  • 14. Mycophenolate mofetil therapy for moderate to severe atopic dermatitis.
    Murray ML, Cohen JB.
    Clin Exp Dermatol; 2007 Jan; 32(1):23-7. PubMed ID: 17059445
    [Abstract] [Full Text] [Related]

  • 15. Tolerability of mycophenolate mofetil in patients with systemic lupus erythematosus.
    Riskalla MM, Somers EC, Fatica RA, McCune WJ.
    J Rheumatol; 2003 Jul; 30(7):1508-12. PubMed ID: 12858449
    [Abstract] [Full Text] [Related]

  • 16. Enteric-coated mycophenolate sodium: safe conversion from mycophenolate mofetil in maintenance renal transplant recipients.
    Budde K, Glander P, Diekmann F, Dragun D, Waiser J, Fritsche L, Neumayer HH.
    Transplant Proc; 2004 Mar; 36(2 Suppl):524S-527S. PubMed ID: 15041401
    [Abstract] [Full Text] [Related]

  • 17. Calcineurin inhibitor-free immunosuppression based on antithymocyte globulin and mycophenolate mofetil in cadaveric kidney transplantation: results after 5 years.
    Grinyó JM, Gil-Vernet S, Cruzado JM, Caldés A, Riera L, Serón D, Rama I, Torras J.
    Transpl Int; 2003 Nov; 16(11):820-7. PubMed ID: 12879230
    [Abstract] [Full Text] [Related]

  • 18. Mycophenolate mofetil vs cyclophosphamide therapy for patients with diffuse proliferative lupus nephritis.
    Hu W, Liu Z, Chen H, Tang Z, Wang Q, Shen K, Li L.
    Chin Med J (Engl); 2002 May; 115(5):705-9. PubMed ID: 12133539
    [Abstract] [Full Text] [Related]

  • 19. Intravenous immunoglobulin may be an effective therapy for refractory, active diffuse cutaneous systemic sclerosis.
    Poelman CL, Hummers LK, Wigley FM, Anderson C, Boin F, Shah AA.
    J Rheumatol; 2015 Feb; 42(2):236-42. PubMed ID: 25433527
    [Abstract] [Full Text] [Related]

  • 20. Impact of mycophenolate mofetil (MMF)-related gastrointestinal complications and MMF dose alterations on transplant outcomes and healthcare costs in renal transplant recipients.
    Tierce JC, Porterfield-Baxa J, Petrilla AA, Kilburg A, Ferguson RM.
    Clin Transplant; 2005 Dec; 19(6):779-84. PubMed ID: 16313325
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.